For millions of women, a diagnosis of endometriosis reshapes daily life around pain, fertility challenges, and a medical system that has historically been slow to take either seriously. Managing the condition itself is hard enough. But a growing body of research is now raising a question that many women haven’t been asked to consider: does endometriosis also carry long-term risks beyond the reproductive years?
The answer, researchers are finding, is more complex than a simple yes or no. The connection between endometriosis and certain cancers has been studied for decades, but the picture became sharper in 2026 with new findings that are starting to change how clinicians think about monitoring their patients. What those findings mean for the tens of millions of women living with this condition deserves a careful, clear-eyed look.
Understanding the risk doesn’t require panic. What it does require is good information. And for women who’ve spent years navigating a condition that is frequently dismissed or misdiagnosed, having that information early may matter more than many doctors have let on.
What Is Endometriosis, and Why Does It Create a Biological Environment for Endometriosis Cancer Risk?
Endometriosis is a hormone-dependent, chronic inflammatory condition. It involves the growth of endometrial-like tissue outside the uterus, which can cause chronic pelvic pain and infertility. The disease affects approximately 10% of reproductive-age women.
What makes endometriosis more than just a painful gynecological condition is what’s happening at the cellular level. As a chronic estrogen-dependent disease, it’s associated with a risk of developing gynecological cancers, and emerging evidence implicates key signaling pathways, including PI3K/AKT/mTOR and ARID1A alterations, in malignant transformation. In plain terms, the tissue lesions that define endometriosis don’t just cause pain. They exist in a biological environment driven by excess estrogen and chronic inflammation, and over time, that environment can trigger cellular changes that raise cancer risk.
Various mechanisms contribute to the malignant transformation of endometriosis, including gene mutations, oxidative stress, inflammation, and epigenetic changes. The disease also resists progesterone (the hormone that normally balances estrogen), which means the estrogen-driven inflammatory cycle tends to sustain itself rather than switch off.
Malignant transformation of endometriosis is associated with genetic alterations including ARID1A mutations and abnormal PI3K/Akt and mTOR pathway activation. A 2025 systematic review from the National and Kapodistrian University of Athens notes that malignant transformation occurs in approximately 0.5 – 1% of cases, most of which develop into endometriosis-associated ovarian cancers such as clear cell and endometrioid adenocarcinomas. Researchers don’t yet have a complete map of how these mechanisms lead to cancer in some women but not others, and that uncertainty is an honest part of the conversation.
The 2026 Swedish Study That Changed the Clinical Conversation
The most recent and significant contribution to this research came in May 2026. Led by Louise Moberg of the Department of Gynaecology and Obstetrics at Skåne University Hospital, Lund University, the study was published online on May 14, 2026, in Acta Obstetricia et Gynecologica Scandinavica. It examined cancer risks in women with endometriosis or adenomyosis and was nationwide in scope.
A nationwide cohort study was conducted between 1997 and 2018. All women diagnosed with endometriosis or adenomyosis in Sweden during that period were followed for cancer diagnosis, with the reference population being women not diagnosed with these conditions. Among women who received a cancer diagnosis in the years after their endometriosis or adenomyosis diagnosis, the risk remained elevated for epithelial ovarian cancer, with a standardized incidence ratio (SIR) of 1.9, and for breast cancer, with a SIR of 1.2. A SIR of 1.9 for ovarian cancer means affected women had roughly 90% higher relative risk compared to the general population. For breast cancer, the 1.2 SIR translates to approximately 20% elevated relative risk.
A total of 49,133 women were diagnosed with endometriosis or adenomyosis at a mean age of 42.7 years, and of these, 1,784 (3.6%) were diagnosed with gynecological or breast cancer. The study authors concluded that clinicians should apply a higher level of suspicion for gynecological or breast cancers in women diagnosed with endometriosis. That’s a pointed message directed at the medical community, calling for more vigilant follow-up and monitoring rather than watchful waiting alone.
Detection bias could not be excluded because women with persistent symptoms often undergo diagnostic procedures that may lead to earlier cancer detection, and the study’s observational design precluded establishing causal inference. Elevated diagnoses in this population may partly reflect the fact that women who stay in contact with the medical system for ongoing endometriosis care are simply more likely to have cancers caught early – which is, counterintuitively, one reason consistent monitoring matters.
Ovarian Cancer: The Strongest and Most Consistent Link
Across the research landscape, ovarian cancer is where the endometriosis cancer risk signal is loudest and most consistent. A meta-analysis pooling data from 67 studies and more than 500,000 women, known as the ENDOCANCER review, was conducted by researchers across multiple Italian institutions and searched published studies through August 2025. Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival. That nuance matters. The news isn’t purely alarming.
Not all ovarian cancer subtypes carry the same degree of risk. A team of researchers led by Dr. Karen Schliep at the University of Utah examined the relationship between endometriosis subtypes and the risk of ovarian cancers, with results published in JAMA on July 17, 2024. That study found that women with endometriosis have four times the risk of developing ovarian cancer compared to those without the condition. The risk was not uniform across endometriosis subtypes. Deep infiltrating endometriosis, which affects organs near the uterus like the bladder and bowels, and endometriomas, which are cysts that form within the ovaries, were associated with more elevated risk.
A pooled analysis of case-control studies provides additional detail on which ovarian cancer types are most connected to endometriosis. The clearest and most consistent association is between endometriosis and two subtypes: endometrioid and clear cell ovarian cancers, often discussed as endometriosis-associated ovarian cancers. A 2013 pooled analysis published in the Lancet Oncology found endometriosis was significantly associated with a higher risk of clear-cell ovarian cancer (OR 3.05), endometrioid ovarian cancer (OR 2.04), and low-grade serous ovarian cancer (OR 2.11).
The strongest associations are seen for clear cell and endometrioid ovarian cancers, the subtypes most closely linked to endometriosis-associated ovarian carcinomas.
Putting Absolute Risk in Perspective
The elevated relative risk figures can be alarming when taken out of context. The absolute numbers tell a different, more grounding story. Endometriosis-associated ovarian cancers tend to be earlier stage and lower grade, with a predominance of clear cell and endometrioid types, and survival outcomes favor endometriosis-associated disease.
The absolute lifetime risk of ovarian cancer in women with endometriosis remains relatively low, estimated at around 1.9%. This distinction is clinically important, as relative risk estimates may appear substantial while still translating into a low absolute probability for most patients.
The evidence also includes endometrial cancer. A 2022 meta-analysis published in BMC Women’s Health analyzed data from 14 cohort studies and seven case-control studies. It found that women with endometriosis had an increased risk of both endometrial cancer (relative risk 1.662) and a modestly increased risk of breast cancer (relative risk 1.082). The researchers noted that the shared estrogen-dependence of endometriosis, endometrial cancer, and breast cancer is a plausible biological explanation.
Breast Cancer: A More Complicated Picture
The breast cancer connection is real but more contested than the ovarian cancer link. Given the relatively high incidence of both endometriosis and breast cancer, investigating the potential connection is of substantial clinical significance, though there is no clear consensus in the literature on the extent to which breast cancer risk is increased in patients with endometriosis.
The 2026 Swedish nationwide study found an elevated SIR of 1.2 for breast cancer among women with endometriosis or adenomyosis. That figure is modest but not negligible, particularly in a study large enough to include an entire country’s data over more than two decades. The shared biological mechanism, where estrogen drives both conditions, offers a plausible thread connecting them.
These hormonal interactions emphasize the estrogen-driven inflammatory loop that sustains lesion survival and may contribute to the cancer-promoting potential of endometriosis. Whether that same loop extends to breast tissue remains an active area of research, and women with endometriosis should discuss their individual breast cancer risk factors with their doctor rather than drawing alarm from the headline figure alone.
What Clinical Risk Factors Should Women Know About?
Clinical risk factors for malignant transformation of endometriosis include advanced age (40 to 60 years), large ovarian endometriomas greater than 9 centimeters, and postmenopausal status. These factors can help clinicians and patients decide together how closely to monitor over time.
Women with severe forms, either deep infiltrating endometriosis, ovarian endometriomas, or both, have an overall ovarian cancer risk that is roughly 9.7 times higher relative to women without endometriosis, according to the 2024 JAMA study. That finding firmly establishes a strong link between endometriosis severity and the risk of developing certain ovarian cancers.
The message here isn’t to induce fear. Most women with endometriosis will never develop cancer. The message is about appropriate vigilance: knowing your disease severity, staying in regular contact with a gynecologist familiar with your history, and understanding that postmenopausal symptoms in a woman with prior endometriosis deserve prompt attention.
Read More: Study: Endometriosis Sufferers More Likely to Develop Heart Disease
What This Means for You
If you’ve been diagnosed with endometriosis, the most practical takeaway from this body of research is not to panic but to be proactive. The elevated cancer risk, while real, is relative rather than absolute. Endometriosis is linked to ovarian cancer risk, but absolute lifetime risk remains low for most patients. What shifts the odds in your favor is early detection, which requires showing up for regular screening and being honest with your doctor about any new or changing symptoms.
Imaging methods such as ultrasound, MRI, and CT are used for ongoing monitoring, alongside biomarkers such as CA-125 and HE4. A 2025 review emphasizes that these biomarkers and standard imaging are used clinically, but specificity is limited, meaning abnormal results don’t automatically equal cancer, and normal results don’t always rule out important disease. Ask your gynecologist what monitoring protocol is appropriate for your stage and severity of disease. Women with large endometriomas, a long history of the condition, or postmenopausal status may warrant more frequent imaging.
The 2026 Swedish study offers perhaps the most direct instruction of all: clinicians should apply a higher level of suspicion when a woman with endometriosis presents with new gynecological or breast symptoms. If your doctor isn’t asking those questions, you’re allowed to raise them yourself. Staying informed, asking for thorough follow-up, and understanding the biological connection between endometriosis cancer risk and long-term health management is exactly the kind of engaged care that leads to better outcomes. The research is clearer than it has ever been. That clarity belongs to you.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Endometriosis Diagnosis Transformed by Game-Changing New Guidelines